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Abstract: Trastuzumab is a monoclonal antibody targeting HER-2. HER-2 overexpression 
has been described in gallbladder cancer and in cholangiocarcinoma. This report describes the 
first case of a patient with HER-2 overexpressing metastatic gallbladder adenocarcinoma and 
responding radiographically and biochemically to trastuzumab alone.
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Case report
AK is a 61-year-old woman who developed right upper quadrant pain and underwent 
a laparoscopic cholecystectomy on January 22, 2013. Operative findings included 
a “porcelain” gallbladder, an apparent liver metastasis, and peritoneal metastases. 
The gallbladder was removed and one liver lesion was biopsied. Pathology confirmed 
a poorly differentiated gallbladder adenocarcinoma and metastatic liver disease. 
 Immunohistochemical stains were strongly positive for CK7, polyclonal CEA, and 
nuclear CDX-2. Based on the histology and immunostaining, the pathologist wrote 
“these findings are consistent with a gallbladder origin”.
On February 5, 2013, chemotherapy was initiated with cisplatinum (25 mg/m2, 
days 1 and 8) and gemcitabine (1,000 mg/m2, days 1 and 8) every 21 days. After two 
cycles, her CA19-9 had increased from 1,070 U/mL to 3,769 U/mL (0–35 U/mL) 
and a computed tomography (CT) scan of her chest/abdomen/pelvis showed “interval 
progression” of her metastatic liver disease (largest liver lesion now 8 × 5 cm).
Immunohistochemical staining revealed “HER-2 immunostain is strongly positive 
in the majority of tumor cells”. The pathologist wrote “The clinical significance of this 
finding in these tumors is unknown”. The pathologist noted that the staining would 
be the equivalent of 3+ by immunohistochemistry for HER-2 had this been a breast 
cancer specimen or a gastric cancer specimen.
Breast and gastric cancers are the only tumors where HER-2 3+ staining is cur-
rently defined. The definition of 3+ staining for breast cancer is “very strong, complete, 
circumferential, membrane staining in 10%–30% of the tumor cells”, and in gastric 
cancer the definition of 3+ staining is strong, complete, basal lateral, or lateral mem-
branous reactivity that is seen in greater than 10% of tumor cells.
On April 9, 2013, therapy was started with weekly paclitaxel (80 mg/m2) and 
trastuzumab (4 mg/kg loading dose followed by 2 mg/m2). Her CA19-9 improved 
from 4,143 U/mL on April 9, 2013 to 1,370 U/mL on May 21, 2013. A CT scan on 
May 20, 2013 showed “interval decrease in the size of the liver metastases”, with the 





largest lesion having decreased in size from 8.5 × 5 cm to 
5.4 × 3.8 cm”. There were no new lesions seen. Paclitaxel 
therapy was discontinued and the patient has remained on 
single-agent trastuzumab weekly. By June 26, 2013, her 
CA19-9 had improved to 432 U/mL and a repeat CT on 
July 1, 2013 showed “interval decrease in the size of the liver 
metastases”, with the largest lesion having decreased in size 
from 5.4 × 3.8 cm to 2.8 × 2.1 cm. She continued to receive 
trastuzumab alone, and a repeat CT scan on September 18, 
2013 showed a further response of her metastatic disease 
to trastuzumab alone, with the largest liver lesion having 
decreased in size from 2.8 × 2.1 cm to 1.3 × 0.8 cm. Again, 
there were no enlarging or new lesions.
Discussion
HER-2 is an ErbB tyrosine kinase family receptor.1,2 In 
breast cancer, trastuzumab is approved by the US Food 
and Drug Administration for use as part of adjuvant and 
metastatic disease therapy in patients with tumors that 
overexpress HER-2 as measured by immunohistochem-
istry (ie, 3+) or show HER-2 gene amplif ication by 
fluorescence in situ  hybridization.3,4 Trastuzumab is also 
approved for use in combination with chemotherapy for 
patients with HER2-overexpressing metastatic gastric 
or gastroesophageal cancers.5
Biliary cancers are relatively rare cancers and include 
adenocarcinomas originating in the gallbladder or bile ducts. 
Once metastatic, these malignancies are considered  incurable. 
Patients randomized to receive gemcitabine and cisplatinum 
showed a small overall survival benefit of 11.7 months 
compared with 8.1 months for those receiving gemcitabine 
alone.6 This combination has consequently become a standard 
first-line therapy for patients with metastatic biliary cancer. 
The cancer in our patient progressed while she received that 
combination, and there is no proven efficacy of second-line 
therapy for metastatic biliary cancer.
Only about 5% of biliary cancers overexpress HER-2.7–10 
AK’s gallbladder adenocarcinoma did overexpress HER-2. 
While there is no formal definition of HER-2 3+ in biliary 
cancers, had her tumor been a breast or gastric cancer, it 
clearly would have met the criteria for HER-2 3+ overex-
pression, as described above. Over the time she received 
trastuzumab alone, her tumor responded both radiographi-
cally and biochemically to trastuzumab alone, with her 
CA19-9 improving from 1,370 U/mL to 432 U/mL and her 
largest liver lesion decreasing in size from 5.5 × 3.8 cm to 
1.3 × 0.8 cm, as noted in the radiology CT reports.
A review of the literature identified a single case report 
of a patient with biliary cancer responding to paclitaxel in 
combination with trastuzumab,11 but no previous report could 
be found of a patient responding to trastuzumab as a single 
agent. In this case, HER-2 overexpression was an actionable 
abnormality.
In summary, this metastatic gallbladder cancer was con-
tinuing to respond biochemically (ie, decreasing CA19-9) 
and radiographically to trastuzumab alone during the interval 
between May 20, 2013 and September 16, 2013. The dura-
bility of this response remains to be seen. Ideally, a study 
of patients with HER-2-overexpressing biliary cancer might 
confirm the benefit of using trastuzumab in patients with 
HER-2-overexpressing biliary cancer.
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